Polymorphism of Baculoviral Inhibitor of Apoptosis Repeat-Containing 5 (BIRC5) Can Be Associated with Clinical Outcome of Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) comprises about 85% of all lung cancers. Currently, NSCLC therapy is based on the analysis of specific predictors, whose presence qualifies patients for appropriate treatment. Baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5), also known as “survivin”,...

Descripción completa

Detalles Bibliográficos
Autores principales: Szczyrek, Michał, Mlak, Radosław, Szudy-Szczyrek, Aneta, Wojas-Krawczyk, Kamila, Kędziora, Karolina, Milanowski, Janusz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946487/
https://www.ncbi.nlm.nih.gov/pubmed/35326407
http://dx.doi.org/10.3390/cells11060956

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946487/
https://www.ncbi.nlm.nih.gov/pubmed/35326407
http://dx.doi.org/10.3390/cells11060956

Ejemplares similares